Cancer Research

T cells, which are among the most powerful weapons in the immune systems of humans and other vertebrates, remain substantially programmed to stay exhausted even many weeks after exposure to a virus ended.

The new technology for cellular immunotherapy shows promising anti-tumor activity in the lab against hard-to-treat cancers driven the KRAS mutation.

Penn researchers are looking to mRNA vaccines for applications outside of infectious diseases, as they can not only prompt strong antibody responses to fight off invaders, like COVID-19, but also potent cytotoxic T cell responses.

The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, but the takeaway is not to change testing guidelines based on race alone, but focus on ensuring equal access to and uptake of testing to minimize disparities in care and outcomes.

Penn scientists have developed a new method for tracing the lineage and gene expression patterns of metastatic cancer at the single-cell level.

An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy.

Richard Phillips, a Presidential Assistant Professor of Neurology and member of the Penn Epigenetics Institute, hopes to bring glioma research out of the “basement.”

Afive-year community outreach and engagement effort more than doubled the percentage of participants, improving access and treatment for a group with historically low representation in cancer research.

With the disruption of cancer care since the pandemic began in March 2020, recent reports are starting to show that the interruption—while still significant—may not be as detrimental as experts originally feared.